Combination therapy before surgery for high-risk pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of drugs (including an oral targeted therapy and an immunotherapy) given before surgery for pancreatic cancer that is hard to remove or has high-risk features. The goal is to shrink the tumor to make surgery more likely to be successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have pancreatic cancer that is either hard to remove (borderline resectable) or at risk of coming back (high-risk).
- You haven't had chemotherapy, radiation, or surgery for this cancer before.
- You don't have a BRCA1/2 or PALB2 gene mutation.
- Blood counts and liver/kidney function are within acceptable ranges.
- You have at least one measurable tumor on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining a targeted drug (surufatinib) and an immunotherapy (serplulimab) with standard chemotherapy can shrink locally advanced pancreatic cancer enough to allow surgery, compared to chemotherapy alone. It aims to improve the chance of successful removal of the tumor.
This trial tests a combination of four drugs given before surgery to shrink pancreatic tumors that are borderline resectable or high-risk. The goal is to make surgery more effective and improve outcomes.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial tests if adding surufatinib to standard chemotherapy before surgery can help people with a certain type of pancreatic cancer. The goal is to see if the combination shrinks the tumor more than chemotherapy alone.
This trial tests a combination of a chemotherapy drug (irinotecan liposome) plus an immunotherapy drug (addebelizumab) given before surgery to people with pancreatic cancer that can be fully removed. The goal is to see if this treatment reduces the chance of the cancer coming back and improves outcomes.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.